
## **Participant Flow**



## **Baseline characteristics**

Variables	Acupuncture group (N =48)	Control group (N=48)	Р
Age (years)	48. 42±14. 11	49. 49±14. 51	0.88
Gender (male/female)	19/29	14/23	0. 12
Height (cm)	163.66±12.20	166.62±8.21	0.20
Weight (kg)	65. 39±11. 52	66.81±14.31	0.61
Systolic blood pressure (mmHg)	119.48±14.92	123.81±16.75	0. 2]
Diastolic blood pressure (mmHg)	73.75±9.90	73. 86±8. 45	0.9
<pre>pulse (times/min)</pre>	76.96±8.93	73.35±10.08	0.08
Breathe (times /min)	19.46±2.56	19.30±2.86	0.78
Disease course (days)	64.69±22.01	61. 35±29. 62	0. 53

## **Outcome measures**

Changes in PSQI, ISI, FS-14 of two groups from 2 weeks post-treatment to 2 weeks follow-up.

Tollow-up.											
		Λ			C 4 1		ANCOVA	ANCOVA			
		Acupunc	cture group		Control	group	F	p			
				Paired							
	Mean	SD	95%C1	t-test	Mean	SD					
				p							
PSQI											
Baseline	15.28	2.99			15.78	2.76	1.04	0.31			
2 weeks											
post-	11.10	3.25	3.42, 4.92	<0.01**	11.04	6.39	0.004	0.95			
treatment											
2 weeks	0.70	0.00	4.50, 0.54	.0.04	10.40	0.70	00.10	.0.04			
follow-up	9.73	3.00	4.58, 6.51	<0.01**	12.48	2.76	30.10	<0.01**			
ISI											
Baseline	17.04	4.72			18.51	5.28	2.46	0.12			
2 weeks											
post-	11.90	5.05	3. 49, 6. 80	<0.01**	15.32	4.20	16.53	<0.01**			
treatment											
2 weeks	0.77	4.50	6 50 0 06	.0.04	10.00	4.00	00.46	.0.04			
follow-up	8.77	4.53	6. 58, 9. 96	<0.01**	13.22	4.03	32.16	<0.01**			
FS-14											
Baseline	8.08	2.90			7.76	3.80	0.26	0.61			
2 weeks											
post-	6.50	3.50	0.48, 2.69	<0.01*	7.54	3.40	2.67	0.11			
treatment			,								
2 weeks			4 40 2 4=		–			0.5			
follow-up	5.79	3.12	1. 12, 3. 47	<0.01**	8.27	3.12	18.37	<0.01**			

Data were presented as Mean  $\pm$  SD; \*p < 0.05; \*\*p < 0.01;CI, confidence interval; ISI, insomnia severity index; FS-14, Fatigue Scale-14

## **Adverse Events**

None of the remaining 96 participants withdrew due to AEs. None of the participants had acupuncture-related AEs in the acupuncture group. For the placebo group, 1 (0.02%) of 48 participants reported the dizziness and fatigue as adverse event. Other discomforts were not reported.